Apifix
7
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
42.9%
3 terminated/withdrawn out of 7 trials
40.0%
-46.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Post-approval Registry Study to Evaluate the Continued Safety and Probable Benefit of the MID-C System for 5 Years Post-Implantation in Adolescent Idiopathic Scoliosis (AIS)
Role: lead
Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis
Role: lead
PMS Evaluation of Safety and Efficacy of the MID-C System 5 Years Post-implantation in AIS
Role: lead
Limited-efficacy Testing of Spring Distraction System (SDS) and Unilateral One-way Rod (MID-C) for Early Onset Scoliosis
Role: collaborator
Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)
Role: lead
Feasibility Evaluation Study of the MID-C Device
Role: lead
Feasibility Study of MID-C for AIS
Role: lead
All 7 trials loaded